YS Biopharma (NASDAQ:YS) stock is falling Monday after the company announced PIKA recombinant COVID-19 vaccine.
YS Biopharma announced interim Phase 2 safety and immunogenicity data for its PIKA recombinant COVID-19 Vaccine.
The interim data were from the Phase 2 part of the Phase 2/3 head-to-head clinical study to evaluate PIKA recombinant COVID-19 vaccine vs. inactivated COVID-19 vaccine.
The interim data analysis of the Phase 2 study presented that the trial met both primary and secondary endpoints, measured by geometric mean titers (GMTs) of neutralizing antibody against Omicron virus and by seroconversion rates on Day 7 and Day 14 post a booster dose administration.
The ongoing Phase 2/3 study was conducted in the Philippines and United Arab Emirates, which finished the enrollment of 300 and 5656 subjects for the Phase 2 and 3 trials, respectively.
A booster dose of PIKA recombinant COVID-19 vaccine in participants who had previously received two or more doses of the inactivated COVID-19 vaccine elicited superior neutralizing immune responses against the Omicron virus to the responses in participants receiving a booster dose of the inactivated COVID-19 vaccine.
The differences of multiple folds of GMTs were observed with a 95% confidence interval of neutralizing antibodies against the Omicron virus.
Price Action: YS shares are down 35.30% at $3.10 on the last check Monday.
